Metformin Treatment and Homocysteine: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Overview

Journal Nutrients

Date 2016 Dec 13

PMID 27941660

Citations 21

Authors

Qianying Zhang

Sheyu Li

Ling Li

Qianrui Li

Kaiyun Ren

Xin Sun

Jianwei Li

Affiliations

Soon will be listed here.

Abstract

The aim of this systematic review is to assess whether metformin could change the concentration of serum homocysteine (Hcy) with and without simultaneous supplementation of B-group vitamins or folic acid. A literature search was conducted in PubMed, EmBase, and Cochrane Central Register of Controlled Trials (CENTRAL) to identify randomized controlled trials (RCTs) reporting the concentration of serum Hcy in metformin-treated adults. Meta-analysis was applied to assess the association between metformin and the changes of Hcy concentration. Twelve publications were included in this study. In the overall analysis, metformin administration was not statistically associated with the change of Hcy when compared with the control treatment (mean difference (MD), 0.40 μmol/L; 95% confidence interval (CI), -0.07~0.87 μmol/L, = 0.10). In the subgroup analysis, metformin was significantly associated with an increased concentration of Hcy in the absence of exogenous supplementation of folic acid or B-group vitamins (MD, 2.02 μmol/L; 95% CI, 1.37~2.67 μmol/L, < 0.00001), but with a decreased concentration of serum Hcy in the presence of these exogenous supplementations (MD, -0.74 μmol/L; 95% CI, -1.19~-0.30 μmol/L, = 0.001). Therefore, although the overall effect of metformin on the concentration of serum Hcy was neutral, our results suggested that metformin could increase the concentration of Hcy when exogenous B-group vitamins or folic acid supplementation was not given.

Citing Articles

Dose-Dependent Relationship Between Long-Term Metformin Use and the Risk of Diabetic Retinopathy: A Population-Based Cohort Study.

Li Y, Huang K, Yang Y, Gau S, Tsai T, Lee C Clin Drug Investig. 2025; 45(3):125-136.

PMID: 39939507 PMC: 11876261. DOI: 10.1007/s40261-025-01421-2.

Atherogenic Effect of Homocysteine, a Biomarker of Inflammation and Its Treatment.

Prasad K Int J Angiol. 2024; 33(4):262-270.

PMID: 39502352 PMC: 11534477. DOI: 10.1055/s-0044-1788280.

Metformin: The Winding Path from Understanding Its Molecular Mechanisms to Proving Therapeutic Benefits in Neurodegenerative Disorders.

Isop L, Neculau A, Necula R, Kakucs C, Moga M, Dima L Pharmaceuticals (Basel). 2023; 16(12).

PMID: 38139841 PMC: 10748332. DOI: 10.3390/ph16121714.

Dose-response association of metformin use and risk of age-related macular degeneration among patients with type 2 diabetes mellitus: a population-based study.

Huang K, Chang Y, Lee C, Gau S, Tsai T, Chung N Front Pharmacol. 2023; 14:1275095.

PMID: 38074151 PMC: 10710142. DOI: 10.3389/fphar.2023.1275095.

Morphological and Functional Remodeling of the Ischemic Heart Correlates with Homocysteine Levels.

Cziraki A, Nemeth Z, Szabados S, Nagy T, Szanto M, Nyakas C J Cardiovasc Dev Dis. 2023; 10(3).

PMID: 36975886 PMC: 10056082. DOI: 10.3390/jcdd10030122.

References

Luque-Ramirez M, Alvarez-Blasco F, Uriol Rivera M, Escobar-Morreale H . Serum uric acid concentration as non-classic cardiovascular risk factor in women with polycystic ovary syndrome: effect of treatment with ethinyl-estradiol plus cyproterone acetate versus metformin. Hum Reprod. 2008; 23(7):1594-601. DOI: 10.1093/humrep/den095. View

Selhub J . Homocysteine metabolism. Annu Rev Nutr. 1999; 19:217-46. DOI: 10.1146/annurev.nutr.19.1.217. View

Inzucchi S, Bergenstal R, Buse J, Diamant M, Ferrannini E, Nauck M . Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2014; 38(1):140-9. DOI: 10.2337/dc14-2441. View

de Jager J, Kooy A, Lehert P, Wulffele M, van der Kolk J, Bets D . Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial. BMJ. 2010; 340:c2181. PMC: 2874129. DOI: 10.1136/bmj.c2181. View

Rajagopal G, Reddy A, Harinarayan C, Suresh V, Bitla A, P V L N Rao S . Effect of lifestyle modification and metformin therapy on emerging cardiovascular risk factors in overweight Indian women with polycystic ovary syndrome. Metab Syndr Relat Disord. 2012; 10(4):273-9. DOI: 10.1089/met.2011.0127. View

Caspary W, Creutzfeldt W . Analysis of the inhibitory effect of biguanides on glucose absorption: inhibition of active sugar transport. Diabetologia. 1971; 7(5):379-85. DOI: 10.1007/BF01219474. View

Bates C, Mansoor M, Pentieva K, Hamer M, Mishra G . Biochemical risk indices, including plasma homocysteine, that prospectively predict mortality in older British people: the National Diet and Nutrition Survey of People Aged 65 Years and Over. Br J Nutr. 2010; 104(6):893-9. PMC: 3445011. DOI: 10.1017/S0007114510001236. View

Sato Y, Ouchi K, Funase Y, Yamauchi K, Aizawa T . Relationship between metformin use, vitamin B12 deficiency, hyperhomocysteinemia and vascular complications in patients with type 2 diabetes. Endocr J. 2013; 60(12):1275-80. DOI: 10.1507/endocrj.ej13-0332. View

Carlsen S, Kjotrod S, Vanky E, Romundstad P . Homocysteine levels are unaffected by metformin treatment in both nonpregnant and pregnant women with polycystic ovary syndrome. Acta Obstet Gynecol Scand. 2007; 86(2):145-50. DOI: 10.1080/00016340600855946. View

10.

Schachter M, Raziel A, Strassburger D, Rotem C, Ron-El R, Friedler S . Prospective, randomized trial of metformin and vitamins for the reduction of plasma homocysteine in insulin-resistant polycystic ovary syndrome. Fertil Steril. 2007; 88(1):227-30. DOI: 10.1016/j.fertnstert.2006.11.071. View

11.

Anderson J, Pena A, Sullivan T, Gent R, DArcy B, Olds T . Does metformin improve vascular health in children with type 1 diabetes? Protocol for a one year, double blind, randomised, placebo controlled trial. BMC Pediatr. 2013; 13:108. PMC: 3728146. DOI: 10.1186/1471-2431-13-108. View

12.

Mazokopakis E, Starakis I . Recommendations for diagnosis and management of metformin-induced vitamin B12 (Cbl) deficiency. Diabetes Res Clin Pract. 2012; 97(3):359-67. DOI: 10.1016/j.diabres.2012.06.001. View

13.

Gatford K, Houda C, Lu Z, Coat S, Baghurst P, Owens J . Vitamin B12 and homocysteine status during pregnancy in the metformin in gestational diabetes trial: responses to maternal metformin compared with insulin treatment. Diabetes Obes Metab. 2013; 15(7):660-7. DOI: 10.1111/dom.12080. View

14.

Wulffele M, Kooy A, Lehert P, Bets D, Ogterop J, Borger van der Burg B . Effects of short-term treatment with metformin on serum concentrations of homocysteine, folate and vitamin B12 in type 2 diabetes mellitus: a randomized, placebo-controlled trial. J Intern Med. 2003; 254(5):455-63. DOI: 10.1046/j.1365-2796.2003.01213.x. View

15.

Moore E, Mander A, Ames D, Kotowicz M, Carne R, Brodaty H . Increased risk of cognitive impairment in patients with diabetes is associated with metformin. Diabetes Care. 2013; 36(10):2981-7. PMC: 3781568. DOI: 10.2337/dc13-0229. View

16.

Derosa G, Franzetti I, Gadaleta G, Ciccarelli L, Fogari R . Metabolic variations with oral antidiabetic drugs in patients with Type 2 diabetes: comparison between glimepiride and metformin. Diabetes Nutr Metab. 2004; 17(3):143-50. View

17.

Derosa G, Mugellini A, Ciccarelli L, Crescenzi G, Fogari R . Comparison of glycaemic control and cardiovascular risk profile in patients with type 2 diabetes during treatment with either repaglinide or metformin. Diabetes Res Clin Pract. 2003; 60(3):161-9. DOI: 10.1016/s0168-8227(03)00057-3. View

18.

Ghazeeri G, Abbas H, Skaff B, Harajly S, Awwad J . Inadequacy of initiating rosuvastatin then metformin on biochemical profile of polycystic ovarian syndrome patients. J Endocrinol Invest. 2015; 38(6):643-51. DOI: 10.1007/s40618-015-0237-3. View

19.

Yilmaz M, Bukan N, Ayvaz G, Karakoc A, Toruner F, Cakir N . The effects of rosiglitazone and metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome. Hum Reprod. 2005; 20(12):3333-40. DOI: 10.1093/humrep/dei258. View

20.

Anderson J, Muhlestein J, Horne B, Carlquist J, Bair T, Madsen T . Plasma homocysteine predicts mortality independently of traditional risk factors and C-reactive protein in patients with angiographically defined coronary artery disease. Circulation. 2000; 102(11):1227-32. DOI: 10.1161/01.cir.102.11.1227. View